A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer ...
Add Yahoo as a preferred source to see more of our stories on Google. A major international trial finds that adding niraparib to standard prostate cancer therapy delays disease progression. (CREDIT: ...
A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay disease progression in men with specific DNA repair gene mutations. In the ...
An international study reports that the combination of two drugs could significantly retard the development of a dangerous form of prostate cancer in men who have specific mutations in DNA repair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results